Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF – Get Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $19.9825, but opened at $20.64. Hikma Pharmaceuticals shares last traded at $20.64, with a volume of 431 shares changing hands.
Hikma Pharmaceuticals Stock Up 2.1%
The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.72 and a current ratio of 1.24. The stock has a 50 day simple moving average of $21.55 and a two-hundred day simple moving average of $24.09.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.
Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.
See Also
- Five stocks we like better than Hikma Pharmaceuticals
- Do not delete, read immediately
- Can Any Expenses Be Deducted From Capital Gains Tax?
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- Forget AI, This Will Be the Next Big Tech Breakthrough
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
